Background Inhaled nitric oxide (iNO) is used as rescue therapy in patients with refractory hypoxemia due to severe COVID-19 acute respiratory distress syndrome (ARDS) despite the …
HQ Cang, XH Quan, XH Chu, Y Liang, X Yang, J Li - Heliyon, 2023 - cell.com
Background Carbapenems and β-lactam and β‐lactamase inhibitors (BLBLIs) have been used empirically in nosocomial pneumonia, but their efficacy and safety are controversial …
The current study examines the direct effect of investment awareness and university education support on students' risky financial investment intentions. Additionally, it examines …
P Fang, K Gao, J Yang, T Li, W Gong… - Infection and Drug …, 2023 - Taylor & Francis
Introduction Sepsis is the most severe infectious disease with the highest mortality rate, particularly among neonates admitted to the neonatal intensive care unit (NICU). This study …
M Gashaw, EK Gudina, S Ali, L Gabriele… - Frontiers in …, 2024 - frontiersin.org
Background In resource-constrained settings, limited antibiotic options make treating carbapenem-resistant bacterial infections difficult for healthcare providers. This study aimed …
Antimicrobial resistance in urinary tract infections (UTIs) is a major public health concern. This study aims to characterize the phenotypic and genetic basis of multidrug resistance …
K Al Sulaiman, O Aljuhani, K Al Aamer… - Journal of Intensive …, 2022 - journals.sagepub.com
Background: Severe coronavirus disease 2019 (COVID-19) can boost the systematic inflammatory response in critically ill patients, causing a systemic hyperinflammatory state …
B Guo, P Li, B Qin, S Wang, W Zhang, Y Shi… - BMC Infectious …, 2024 - Springer
Objective This study aimed to explore the characteristics of carbapenem-resistant Enterobacterales (CRE) patients in the intensive care unit (ICU) in different regions of Henan …
Abstract Background Tocilizumab is an IgG1 class recombinant humanized monoclonal antibody that directly inhibits the IL-6 receptor. Several randomized clinical trials have …